Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big Pharma More Comfortable Giving Acquired Firms Independence

Executive Summary

Big pharma appears increasingly comfortable giving acquired companies operational independence

You may also be interested in...



Pfizer Embraces Biotech-Like Speed To Advance BCMA Bispecific

Chris Boshoff, Pfizer Oncology chief development officer, said lessons from the rapid pace of the company’s COVID-19 vaccine program are being applied to elranatamab and other cancer therapies.

Pfizer’s Tanezumab For Pain Turns Heads At Rheumatology Meeting

Firm looking at 2011-2012 filing for drug candidate, now in Phase III.

Astra Values Entrepreneurial Spirit, Keeps R&D “Armies” Away From CAT

AstraZeneca seeks to preserve the entrepreneurial spirit of its acquisitions by giving them the opportunity to operate differently. "Our strategy is ... to bring them into the AstraZeneca family, but make sure they've got the opportunity to operate differently," CEO David Brennan said during AstraZeneca's fourth quarter earnings call Feb. 1

Related Content

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel